TP53 and Burkitt lymphoma: In conclusion, our study provides evidence that this drug combination increases p53-dependent apoptosis in Burkitt’s lymphoma, as evidenced by the upregulation of cleaved PARP, cleaved caspase-3, TP53, and PUMA.